



UNIVERSITY of NORTH TEXAS HEALTH SCIENCE CENTER

Technology Transfer & Commercialization

## Treatment for Dry Eye Diseases

### Learn more!

Robert McClain, PhD  
Associate Vice President  
[rmclain@hsc.unt.edu](mailto:rmclain@hsc.unt.edu)  
817-735-2618

**Technology Case**  
2007-12

**Our Inventors**  
*Dr. Peter Koulen*

**Patent Status**  
PCT Application filed

3500 Camp Bowie Blvd  
Fort Worth, TX 76107  
Phone: 817-735-5147  
FAX: 817-735-5485  
[techtransfer@hsc.unt.edu](mailto:techtransfer@hsc.unt.edu)

### Discovery

- Bio-mimetic, organometallic compounds for the treatment and prevention of dry eye diseases and other degenerative or acute diseases affecting the lacrimal gland accompanied by altered quality and quantity of tear production

### Features

- Reduces cellular degeneration induced by oxidative stress
- Defined mechanistic component
- Therapy is designed for prevention, rather than palliation

### Benefits

- Reduces damage to the ocular gland tissue and allows preservation of gland function
- Discovery represents efficacy, safety, and application in a convenient topical dosage form

### Opportunities

- Approximately 20% of cases presenting to eye care practitioners involve dry eye disorders, with a potentially larger patient population undergoing self-medicative treatment with OTC product—up to 75% of the US population.
- Treatments that can prevent external or intrinsic impact on ocular gland tissue and function in dry eye disorders are lacking, even though several palliative approaches (e.g., eye drops) are currently in use.
- Potential combination therapies with immuno-modulatory or palliative drugs could provide superior options for treatment of dry eye disorders

8/24/09